 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.236.933 |
| Chemical and physical data | |
| Formula | C19H26O2 |
| Molar mass | 286.415 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Cannabidivarin (CBDV,GWP42006) is a non-intoxicatingpsychoactivecannabinoid found inCannabis. It is ahomolog (chemistry) ofcannabidiol (CBD), with theside-chain shortened by twomethylene bridges (CH2 units).
Although cannabidivarin (CBDV) is usually a minor constituent of the cannabinoid profile, enhanced levels of CBDV have been reported in feral populations ofC. indica ( =C. sativa ssp.indica var.kafiristanica) from northwestIndia, and inhashish fromNepal.[1][2][3]
CBDV demonstrated anticonvulsant in rodent models in a single published study.[4] It was identified for the first time in 1969 by Vollner et al.[5]
Similarly to CBD, it has seven double bond isomers and 30 stereoisomers (see:Cannabidiol#Isomerism). It is not scheduled byConvention on Psychotropic Substances. It is being actively developed byGW Pharmaceuticals (as GWP42006)[6] because of a demonstrated neurochemical pathway for previously observed anti-epileptic and anti-convulsive action.[7] GW has begun several Phase-2 trials for adultepilepsy,[8] for childhood epilepsy and for Prader-Willi Syndrome.[9][10]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |